Fonds de solidarité FTQ puts $5 mln more to work in IMV
Fonds de solidarité FTQ has invested $5 million in IMV Inc (TSX, Nasdaq: IMV), a clinical-stage biopharmaceutical company with offices and labs in Halifax and Québec City. The investment forms part of a $29.5 million public offering announced this week. The Fonds, a Canadian growth capital provider, has to date invested $10.75 million in the company. IMV will use the offering's proceeds mainly to accelerate development of new immunotherapies for people facing cancer using its drug release platform DPX-Survivac. Founded in 2000 and led by CEO Frédéric Ors, IMV is also backed by Canadian life sciences venture capital firm CTI Life Sciences Fund.
11 March 2019•2 mins read
